Navigation Links
Verenium Announces Up to $16 Million in New Secured Financings
Date:10/20/2011

SAN DIEGO, Oct. 20, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company developing and commercializing high-performance enzymes, today announced that it has entered into an agreement with Comerica Bank and the Export-Import Bank of the United States ("Ex-Im Bank") for two 18-month, secured revolving credit facilities totaling up to $13 million.

These new credit facilities will allow the Company to borrow up to $10 million against its eligible foreign receivables, and up to $3 million against its eligible domestic receivables and inventory. Borrowings under the facilities will bear interest at the daily LIBOR plus 6%. The proceeds of these facilities will be used for general working capital purposes.

Separately, the Company has also put in place a facility for up to $3 million in secured equipment financing to help support the planned build-out of its research and bioprocess development laboratories and corporate headquarters in San Diego.

"We are very pleased with the flexibility these new facilities provide the Company, and that we have addressed a portion of our financing needs with non-dilutive sources of capital," said Jeffrey Black, Chief Financial Officer at Verenium. "These credit facilities allow us to utilize existing assets to support the general working capital needs of the Company, and will provide us with available borrowing capacity to support the anticipated growth of our sales. In addition, the structure of these facilities will enable us to leverage certain additional assets, including our intellectual property, for additional secured financing."

About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's ability to borrow under its new credit facilities and other financing commitment, its financing needs and the extent to which its new credit facilities and other financing commitment address those needs, its ability to obtain additional financing, its lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's ability to generate adequate receivables and inventory to enable it to access its new credit facilities in desired amounts, ability to maintain compliance with its covenants and other obligations contained in the new credit facilities and other financing commitment, strategic focus, technologies, ability to obtain additional financing to support its planned operations and financial obligations, dependence on patents and proprietary rights, protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.Contacts:Kelly Lindenboom

Vice President, Corporate Communications

858-431-8580

kelly.lindenboom@verenium.com

Sarah Carmody

Manager, Corporate Communications

858-431-8581

sarah.carmody@verenium.com
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Verenium Announces Debt Repurchase
2. Verenium to Present at Upcoming Conferences
3. Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011
4. Verenium Announces Debt Repurchase
5. Verenium Announces Signing of Lease for New Office and Lab Space
6. Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes
7. Verenium Receives CLARUS Award at MDB Capitals Bright Lights Conference 2011
8. Verenium to Present at Upcoming Conferences
9. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
10. Verenium to Present at MDB Capital Groups Bright Lights Conference
11. Verenium Announces Debt Repurchase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... as insulin, cortisol, CRP, adiponectin, uric acid, and/or other biomarkers or SNPs of ... Assay from Salimetrics’ SalivaLab , the relationship between insulin and other relevant ...
Breaking Biology Technology:
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):